Birchtech Corp
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2004-03-04
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.bchtpharm.com
Clinical Trials
13
Active:0
Completed:2
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:2
Phase 2:2
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (23.1%)Early Phase 1
2 (15.4%)Phase 1
2 (15.4%)Phase 2
2 (15.4%)Phase 3
2 (15.4%)Phase 4
2 (15.4%)Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Not Applicable
Not yet recruiting
- Conditions
- Prevention of Influenza
- Interventions
- Biological: Test GroupBiological: Placebo Group
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Changchun BCHT Biotechnology Co.
- Target Recruit Count
- 6680
- Registration Number
- NCT07133802
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Not Applicable
Recruiting
- Conditions
- Prevent Whooping CoughPrevent DiphtheriaPrevent Tetanus
- Interventions
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Changchun BCHT Biotechnology Co.
- Target Recruit Count
- 1650
- Registration Number
- NCT07112144
- Locations
- 🇨🇳
Yanshan County Center for Disease Control and Prevention, Wenshan Zhuang and Miao Autonomous Prefecture, Yunnan, China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
Phase 4
Not yet recruiting
- Conditions
- Prevention of Herpes Zoster
- Interventions
- Biological: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Changchun BCHT Biotechnology Co.
- Target Recruit Count
- 600
- Registration Number
- NCT06961721
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
Phase 2
Not yet recruiting
- Conditions
- Rabies Virus Infection
- Interventions
- Drug: Natural full human monoclonal antibody CBB 1 injection 50.0µg/kgDrug: Natural full human monoclonal antibody CBB 1 injection 100.0µg/kgDrug: Rabies Human Immunoglobulin (HRIG)Biological: Lyophilized rabies vaccine for human use (Vero cells)
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Changchun BCHT Biotechnology Co.
- Target Recruit Count
- 120
- Registration Number
- NCT06548139
- Locations
- 🇨🇳
The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Early Phase 1
Not yet recruiting
- Conditions
- Clostridium Tetanus
- Interventions
- Drug: Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparationDrug: Tetanus human immunoglobulin (HTIG)Drug: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placeboBiological: Adsorbed tetanus vaccine (TT)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Changchun BCHT Biotechnology Co.
- Target Recruit Count
- 190
- Registration Number
- NCT06360250
- Prev
- 1
- 2
- 3
- Next
News
Tetanus Clinical Trial Pipeline Shows Promise with 20+ Drugs in Development
The tetanus clinical trial landscape is robust, featuring over 20 active players developing novel therapies to combat this severe bacterial infection.